GW Pharmaceuticals plc announced that the European Commission (EC) has approved the Type II variation application for Epidyolex (cannabidiol) as an adjunctive treatment of seizures associated with TSC,… read more.
GW Pharmaceuticals plc , a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
